Anixa Biosciences Inc (ANIX) stock
ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
$2.62−0.06 (-2.24%)
Close on Nov 13, 2026Market cap $91.08MP/E –Yield –
Anixa Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Anixa Biosciences's profit margin for the twelve months ending Oct 31, 2023 was -4671.9%. For fiscal 2024 it was -5978.1%, against -4671.9% the year before. The highest annual figure on record is -14.9% in fiscal 2015.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | -5978.1% | −1306.2 |
| FY2023 | Oct 31, 2023 | -4671.9% | −2141.8 |
| FY2021 | Oct 31, 2021 | -2530.1% | +2128.7 |
| FY2019 | Oct 31, 2019 | -4658.8% | −3400.8 |
| FY2018 | Oct 31, 2018 | -1258.1% | +123.7 |
| FY2017 | Oct 31, 2017 | -1381.8% | +290.4 |
| FY2016 | Oct 31, 2016 | -1672.1% | −1657.2 |
| FY2015 | Oct 31, 2015 | -14.9% | +247.0 |
| FY2014 | Oct 31, 2014 | -261.9% | +2330.3 |
| FY2013 | Oct 31, 2013 | -2592.3% | −2139.9 |
| FY2012 | Oct 31, 2012 | -452.4% | +283.0 |
| FY2011 | Oct 31, 2011 | -735.5% | −27.2 |
| FY2010 | Oct 31, 2010 | -708.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -1089.5% | −905.7 |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | -746.4% | −251.4 |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | -430.4% | +93.4 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | -1510.9% | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -183.8% | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -495.0% | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -523.8% | – |
See a number that looks wrong?